Efficacy of pre operative Tegafur/Uracil and Degarelix combination therapy for high risk prostate cancer

Efficacy of pre operative Tegafur/Uracil and Degarelix combination therapy for high risk prostate cancer - Efficacy of pre operative Tegafur/Uracil and Degarelix combination therapy for high risk prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036159

Enrollment

100

Registered

2019-04-01

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

This study is single arm study. Control group is historical cohort.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: High risk prostate cancer patients who will be received radical prostatectomy.

Exclusion criteria

Exclusion criteria: Patient who is difficult to obtain his consent.

Design outcomes

Primary

Measure	Time frame
survival rate after radical prostatectomy	—

Secondary

Measure	Time frame
Adverse event	—

Countries

Japan

Contacts

Public ContactTaku Kato

Gifu University Graduate School of Medicine Department of Urology

urojim@gifu-u.ac.jp0582306338

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026